Immunologic Factor
rituximab
[ rih-tuk-sih-mab ]
Brand Names:
Riabni; Rituxan; Rituxan Hycela; Ruxience; Truxima
Effect:
Increased Cellular Death
May Treat:
Arthritis, Rheumatoid;
Granulomatosis with Polyangiitis;
Leukemia, Lymphoid;
Lymphoma, B-Cell;
Lymphoma, Mantle-Cell;
Microscopic Polyangiitis
More Information:
Definitions related to rituximab:
-
A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.NCI Dictionary of Cancer TermsU.S. National Cancer Institute, 2021
-
A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS.NLM Medical Subject HeadingsU.S. National Library of Medicine, 2021
-
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)NCI ThesaurusU.S. National Cancer Institute, 2021
Return to OpenMD Medical Dictionary
> R
This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.